Lyon: AKESO(09926) target price raised to HK$95.3, rated "outperform market"

Lyon released a research report stating that AKESO (09926) product sales increased by 25.3% year-on-year, and the bank believes that the sales of AK104 and AK112 should meet the company's expectations. The company's management revealed that since AK112 was included in the National Reimbursement Drug List (NRDL) earlier this year, its sales have achieved good growth. The bank has raised its target price from 72.1 Hong Kong dollars to 95.3 Hong Kong dollars, maintaining a "outperform" rating.